Key takeaways
Gilenya (fingolimod) and Aubagio (teriflunomide) are both oral medications used to treat relapsing forms of multiple sclerosis (MS), but they work in different ways. Gilenya is a sphingosine 1-phosphate receptor modulator that lowers the number of white blood cells to reduce nerve damage, while Aubagio is a pyrimidine synthesis inhibitor that calms the immune system by blocking a specific enzyme. Gilenya can be used in both adults and children aged 10 and older, whereas Aubagio is only for adults. Gilenya requires close monitoring for heart issues, especially during the first dose, and can cause serious side effects like infections and liver problems. Aubagio also has serious risks, including liver damage and severe skin reactions, and it can stay in your body for up to two years after stopping. Both medications are not safe during pregnancy and require birth control use. Gilenya is available in two forms: a capsule and an orally disintegrating tablet, while Aubagio is only available as a tablet.
